Rabies Vaccine Allergy
Conditions
Brief summary
The objective of this study was to achieve the post-marketing protective effect research of Speeda® rabies vaccine for human use from Chengda Bio.
Detailed description
When found the injury who is bitten by the animal to three-level, the investigators would enroll the participant after explaining the protection and making him signed the informed consent. The patient would inject rabies vaccine as follow the national regulation, meanwhile the investigators would get the blood samples to detect whether the man-killer carries the rabies virus.
Interventions
BIOLOGICALrabies vaccine
Injection on day 0、7、21
Sponsors
Beijing Center for Disease Control and Prevention
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Healthy volunteers
Yes
Inclusion criteria
* Parent/legal acceptable representatives of children or the adult participants are willing and able to understand the protocol requirements and provide informed consent signed * Participant is considered to be in good health including the body and mental status on the basis of reported medical history and limited physical examination and live in local ≥ 12 months before injured * The man-killer could found and detect whether it carries the virus
Exclusion criteria
* Known bleeding disorder or suspected impairment of immunologic function, or receipt of immunosuppressive therapy or immunoglobulin since birth * Apply passive immunity preparation
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Observation of the subject after injured by the animals carrying the virus | 2 years | Whether or when would the patients develop symptoms after injured by the animals carrying the virus |
Countries
China
Outcome results
None listed